Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in Utah: - Intermountain Medical Center ( Site 0113) — Murray, Utah
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients…
Sponsor: BeOne Medicines
NCT ID: NCT07492641
Sites in Utah: - Utah Cancer Specialists Cancer Center — Salt Lake City, Utah
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Utah: - Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
Phase 3 Recruiting Academic/Other
The goal of this study is to assess the effect of brief mindfulness-guided meditations during radiation therapy (RT) for patients with anxiety related to RT for breast and gynecological cancers.
Sponsor: University of Utah
NCT ID: NCT07166042
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Utah: - Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Industry
This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant…
Sponsor: Eli Lilly and Company
NCT ID: NCT07287098
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
Sponsor: Jacobio Pharmaceuticals Co., Ltd.
NCT ID: NCT05490472
Sites in Utah: - University of Utah Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The goal of this study is to evaluate 5 days vs. 9 days of whole breast radiation.
Sponsor: University of Utah
NCT ID: NCT06961955
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.
Sponsor: University of Utah
NCT ID: NCT05464082
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Phase 1 Recruiting Industry
The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main que…
Sponsor: NiKang Therapeutics, Inc.
NCT ID: NCT07029399
Sites in Utah: - South Texas Accelerated Research Therapeutics (START) Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how …
Sponsor: Eli Lilly and Company
NCT ID: NCT07046923
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with a…
Sponsor: Cogent Biosciences, Inc.
NCT ID: NCT07361562
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to e…
Sponsor: Aktis Oncology, Inc.
NCT ID: NCT07020117
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1 Recruiting Industry
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumo…
Sponsor: NextCure, Inc.
NCT ID: NCT06774963
Sites in Utah: - Intermountain/LDS Hospital Ph 1 Research Program — Salt Lake City, Utah
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study als…
Sponsor: Pfizer
NCT ID: NCT07318805
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry
This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in ad…
Sponsor: Cogent Biosciences, Inc.
NCT ID: NCT07383506
Sites in Utah: - START Mountain Region, LLC — West Valley City, Utah
Phase 1 Recruiting Industry
The purpose of this study is to test BTX-9341 alone or in combination with fulvestrant (a currently marketed medication for breast cancer) in participants with advanced and/or metastatic hormone receptor positive (HR+)/human epidermal grow…
Sponsor: Biotheryx, Inc.
NCT ID: NCT06515470
Sites in Utah: - Biotheryx Investigative Site — West Valley City, Utah
EARLY Phase 1 Recruiting Academic/Other
This is an open-label, single arm, single center, non-randomized feasibility study of the Muse MRgFUS System in subjects with breast cancer. Subjects will undergo partial ablation of half (≤50%) of one of their tumors (if multifocal or mul…
Sponsor: University of Utah
NCT ID: NCT05291507
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
NA Recruiting Network
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using marke…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03723928
Sites in Utah: - American Fork Hospital / Huntsman Intermountain Cancer Center — American Fork, Utah
- Sandra L Maxwell Cancer Center — Cedar City, Utah
- Logan Regional Hospital — Logan, Utah
- Intermountain Medical Center — Murray, Utah
- McKay-Dee Hospital Center — Ogden, Utah
NA Recruiting Academic/Other
The study will assess the efficacy of a standardized postoperative patient-centered intervention designed to educate patients on the opioid epidemic, the judicious use of opioids, and the proper disposal of opioids. This trial is a single-…
Sponsor: University of Utah
NCT ID: NCT07044583
Sites in Utah: - University of Utah Huntsman Cancer Institute — Salt Lake City, Utah